Myeloma
Myeloma
The latest news, research, and perspectives in multiple myeloma. Multiple myeloma is characterized by the proliferation of malignant plasma cells that accumulate in the bone marrow and produce abnormal immunoglobulin. Read more about the pathophysiology, diagnosis, staging, and treatment of myeloma.
Advertisement
Nichole TuckerMyeloma | July 9, 2025
Next-gen BCL-2 inhibitors show promise in RRMM as venetoclax struggles with OS in phase 3 BELLINI study.
Saad Z. Usmani, MD, MBA, FACPMyeloma | July 8, 2025
Experts explore inflammation, immune escape, and diverging approaches in managing precursor myeloma.
Melissa BadamoAcute Lymphoblastic Leukemia | July 7, 2025
Gaps in coordination and collaboration between primary care and oncology may impact long-term survival outcomes for patients.
Saad Z. Usmani, MD, MBA, FACPMyeloma | July 3, 2025
Experts discuss quadruplet therapy, MRD, and evolving transplant decisions in newly diagnosed multiple myeloma.
Saad Z. Usmani, MD, MBA, FACPMyeloma | July 8, 2025
Experts debate immune escape, inflammation, and early intervention in relapsed/refractory multiple myeloma.
Nichole TuckerMyeloma | July 3, 2025
Linvoseltamab earns FDA nod for RRMM with 70% ORR, monthly dosing, and lower CRS than other bispecifics.
Advertisement
Rahul Banerjee, MD, FACPMyeloma | June 24, 2025
Blood Cancers Today editors Krina Patel and Rahul Banerjee reflect on paradigm-shifting myeloma research from ASCO.
Izzah NawazMyeloma | June 23, 2025
A U.S. claims database study revealed how clinicians are administering elranatamab therapy in the real-world setting.
Melissa BadamoMyeloma | June 16, 2025
Talquetamab plus teclistamab yields high responses in patients with relapsed/refractory myeloma and extramedullary disease.
Susan Bal, MDMeeting News | June 23, 2025
Dr. Susan Bal unpacks the promise of GPRC5D CAR T therapy in relapsed/refractory multiple myeloma.
Robert ZadottiMeeting News | June 14, 2025
Elotuzumab added to KRd shows a favorable trend in 3-year PFS for NDMM patients, EHA 2025 study finds.
Izzah NawazMeeting News | June 14, 2025
Talquetamab remains effective in tough-to-treat myeloma—even when patients develop immune responses.
Melissa BadamoMyeloma | June 13, 2025
The ratio of T cells to neutrophils at the time of leukapheresis was associated with better outcomes, Dr. Voorhees explained.
Melissa BadamoMyeloma | June 16, 2025
Isatuximab added to bortezomib, lenalidomide, and dexamethasone showed a significant PFS benefit in myeloma.
Izzah NawazMyeloma | June 11, 2025
Elranatamab shows durable responses and manageable safety in heavily pretreated US patients with myeloma.
Izzah NawazMeeting News | June 11, 2025
Blood clot risk tools may fall short for myeloma patients—study shows aspirin alone might not be enough.
Izzah NawazMeeting News | June 11, 2025
Belantamab may return for RRMM after DREAMM trials show benefit, despite ongoing concerns about eye toxicity.
Andrew MorenoMeeting News | June 11, 2025
The three-arm study enrolled patients with disease refractory to prior carfilzomib, daratumumab, or pomalidomide therapy.
Melissa BadamoMyeloma | June 10, 2025
At 5 years, 33% of patients with myeloma receiving cilta-cel in the CARTITUDE-1 trial are alive and disease free.
Melissa BadamoMyeloma | June 11, 2025
The median progression-free survival was 33.2 months in the BVd arm, compared with 11.1 months in the DVd arm.
Advertisement
Advertisement